Compare FSSL & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FSSL | ANL |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.4M | 998.8M |
| IPO Year | 2025 | 2022 |
| Metric | FSSL | ANL |
|---|---|---|
| Price | $11.84 | $10.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.50 |
| AVG Volume (30 Days) | 235.4K | ★ 268.1K |
| Earning Date | 01-01-0001 | 08-14-2026 |
| Dividend Yield | ★ 15.05% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $243.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.75 | $0.88 |
| 52 Week High | $14.49 | $17.25 |
| Indicator | FSSL | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 53.50 | 46.74 |
| Support Level | $11.78 | $8.95 |
| Resistance Level | $11.91 | $11.90 |
| Average True Range (ATR) | 0.25 | 0.99 |
| MACD | 0.03 | 0.25 |
| Stochastic Oscillator | 56.02 | 72.55 |
FS Specialty Lending Fund is a United States-based externally managed, non-diversified, closed-end management investment company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation by investing mainly in private and public credit in a broad set of industries, sectors, and sub-sectors. Its investment policy is to invest mainly in a portfolio of secured and unsecured floating and fixed-rate loans, bonds, and other types of credit instruments, which, under normal circumstances, will represent at least eighty percent of the Company's total assets.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.